Nav: Home

First line combination therapy improves progression-free survival in advanced lung cancer

December 07, 2017

LUGANO-GENEVA, Dec. 7, 2017 - A new combination therapy for the first line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS), according to results of the phase III IMpower150 trial presented at the ESMO Immuno Oncology Congress 2017. (1)

"This is the first phase III trial to report on the combination of chemotherapy, antiangiogenic treatment and immunotherapy as first line treatment for advanced non-squamous NSCLC," said lead author Professor Martin Reck, chief oncology physician, Department of Thoracic Oncology, Lung Clinic Grosshansdorf, Germany. "The trial met its co-primary endpoint of PFS and the preliminary results of the co-primary endpoint of overall survival (OS), although immature, look encouraging."

There is a scientific rationale to support the combinations that have been explored in the trial. Bevacizumab may enhance the ability of atezolizumab to restore anti-cancer immunity by inhibiting vascular endothelial growth factor (VEGF)-related immunosuppression and other mechanisms while chemotherapy may induce immune responses. The chemotherapy used in the trial was carboplatin plus paclitaxel. Atezolizumab is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1), while bevacizumab is a biologic antiangiogenic drug.

IMpower150 enrolled 1,202 patients who were randomised to one of three arms: A) chemotherapy plus atezolizumab; B) chemotherapy plus atezolizumab plus bevacizumab; or C) chemotherapy plus bevacizumab.

The PFS survival comparison was made between arms B and C and showed that the combination of atezolizumab, bevacizumab and chemotherapy was superior to bevacizumab and chemotherapy alone with a median PFS of 8.3 versus 6.8 months (hazard ratio [HR] 0.62; 95% confidence interval [CI] 0.52, 0.74; P < 0.0001) in the intention-to-treat (ITT) wild type (WT) population, which excluded patients with epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.

The corresponding median PFS in the Teff-WT population, which included patients with defined expression of a T-effector gene signature in the tumour tissue, was 11.3 versus 6.8 months (HR 0.51; 95% CI 0.38, 0.68; P < 0.0001). PFS benefit was seen regardless of PD-L1 immunohistochemistry status, including PD-L1-negative pts (TC0/IC0: HR 0.77; 95% CI 0.61, 0.99). (2)

There were no new safety signals with the combination therapy. Due to prespecified testing hierachy, Arm A versus C has not been formally tested yet.

Reck said: "There was a significant and clinically relevant improvement in progression-free survival favouring the addition of atezolizumab to bevacizumab and chemotherapy. The results show that there is a way to improve the efficacy of platinum-based chemotherapy in patients with advanced non-squamous NSCLC. There were no new safety signals or toxicity issues with this combination so it appears to be a feasible approach for this group of patients."

Commenting on treatment for advanced non-squamous NSCLC for ESMO, Professor Solange Peters, Head of Medical Oncology, Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland, said: "Immunotherapy is a standard of care treatment after platinum-based chemotherapy in patients with advanced NSCLC. Frontline immunotherapy alone is beneficial in those with a high PD-L1 expression, who make up less than a third of NSCLC patients. (3) The combination of immunotherapy and platinum-based chemotherapy showed positive response rates in unselected non-squamous patients (without PD-L1 selection) in a hypothesis-generating phase II trial, which led to US Food and Drug Administration (FDA) approval." (4)

"IMpower150 is the first phase III randomised trial to formally evaluate the combination of immunotherapy and chemotherapy versus chemotherapy frontline," she continued. "The backbone therapy includes bevacizumab which might, by targeting VEGF, facilitate the immune response and the trafficking of T cells. Median PFS for the immunotherapy arm in patients without EGFR mutations or ALK rearrangements had a promising hazard ratio of 0.62 and a median PFS improvement of a little less than two months."

Peters said the benefit of immunotherapy is best observed at later time points. "When you look at the 12-month PFS, you double the number of patients who have not progressed from 18% without immunotherapy to 37% when you add the immunotherapy," she said. "This is very, very promising. Doubling PFS at one year is something we have not seen with any targeted therapy in unselected patients to date."

Even more important was that the combination of chemotherapy and immunotherapy was beneficial regardless of expression of PD-L1 or a T-effector gene signature. It was also beneficial in patients with alterations in EGFR and ALK, who usually do not do well with immunotherapy. Peters said: "We know that for immunotherapy monotherapy, we need to highly select patients for PD-L1 expression. This trial shows that by combining chemotherapy and immunotherapy you completely delete any need for patient selection according to a particular biomarker. This strategy has the potential to benefit large numbers of patients with advanced NSCLC without the practical difficulties of biomarker testing."

Peters concluded: "These exciting results pave the way for a new standard of care in advanced non-squamous NSCLC. The initial overall survival data looks encouraging, but we must wait for it to mature. We will also need to understand the impact of this combination in patients who have already received other immunotherapies. In the next year, other trials will report results in frontline treatment-naïve NSCLC patients using the combination of chemotherapy and immunotherapy or the combination of two immunotherapy drugs. The challenge will then be to judge which strategy is the best."
-end-
Notes to Editors

Please make sure to use the official name of the meeting in your reports: ESMO Immuno Oncology Congress 2017
Official hashtag: #ESMOImmuno17

References and notes

1 Abstract LBA1_PR 'Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/? bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMpower150)' will be presented by Martin Reck during the Proffered Paper session 'Combining immune checkpoint inhibitors and VEGF targeted therapies in cancer treatment' on Thursday, 7 December, 18:15 to 19:15 (CET) in Room A. Annals of Oncology, Volume 28, 2017 Supplement 11.

2 PD-L1 expression was assessed on both tumour cells (TC) and tumour-infiltrating immune cells (IC); and patients were scored as TC 0,

1, 2, or 3 and IC 0, 1, 2, or 3 with an immunohistochemistry test.

3 Reck M, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016; 375:1823-1833.

4 Langer CJ, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17(11):1497-1508.

Disclaimer

This press release contains information provided by the authors of the highlighted abstracts and reflects the content of those abstracts. It does not necessarily reflect the views or opinions of ESMO who cannot be held responsible for the accuracy of the data. Commentators quoted in the press release are required to comply with the ESMO Declaration of Interests policy and the ESMO Code of Conduct.

About the European Society for Medical Oncology (ESMO)

ESMO is the leading professional organisation for medical oncology. With 17,000 members representing oncology professionals from 150 countries worldwide, ESMO is the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evolving professional environment.

http://www.esmo.org

Twitter:esmo.org
Youtube: ESMOchannel

European Society for Medical Oncology

Related Chemotherapy Articles:

Chemotherapy drug may increase vulnerability to depression
A chemotherapy drug used to treat brain cancer may increase vulnerability to depression by stopping new brain cells from growing, according to a new King's College London study out today in Translational Psychiatry.
Sperm changes documented years after chemotherapy
A Washington State University researcher has documented epigenetic changes in the sperm of men who underwent chemotherapy in their teens.
Depressed patients are less responsive to chemotherapy
A brain-boosting protein plays an important role in how well people respond to chemotherapy, researchers report at the ESMO Asia 2016 Congress in Singapore.
Breast cancer study predicts better response to chemotherapy
It is known from previous research that the ER-beta estrogen receptor often has a protective effect.
Personalizing chemotherapy to treat pediatric leukemia
A team of UCLA bioengineers has demonstrated that its technology may go a long way toward overcoming the challenges of treatment for acute lymphoblastic leukemia, among the most common types of cancer in children, and has the potential to help doctors personalize drug doses.
How gut microbes help chemotherapy drugs
Two bacterial species that inhabit the human gut activate immune cells to boost the effectiveness of a commonly prescribed anticancer drug, researchers report Oct.
Molecule prevents effect of chemotherapy
For the last three years the research team has been working on the development of a so-called biomarker to predict treatment effectiveness.
Study provides new clues to leukemia resurgence after chemotherapy
For the first time, researchers have discovered that some leukemia cells harvest energy resources from normal cells during chemotherapy, helping the cancer cells not only to survive, but actually thrive, after treatment.
Dialing up chemotherapy for pancreatic cancer with ultrasound
Researchers at Haukeland University Hospital in Bergen, Norway have combined a laboratory ultrasound technique called 'sonoporation' with the commercially-available chemotherapy compound Gemcitabine to increase the porosity of pancreatic cells with microbubbles and to help get the drug into cancer cells where it is needed.
Vitamin A may help improve pancreatic cancer chemotherapy
The addition of high doses of a form of vitamin A could help make chemotherapy more successful in treating pancreatic cancer, according to an early study by Queen Mary University of London.

Related Chemotherapy Reading:

Physicians' Cancer Chemotherapy Drug Manual 2018
by Edward Chu (Author), Vincent T. DeVita Jr. (Author)

Chemotherapy and Biotherapy Guidelines and Recommendations for Practice
by Martha Polovich (Author), MiKeala Olsen (Author), Kris Lefebvre (Author)

The Chemotherapy Survival Guide: Everything You Need to Know to Get Through Treatment
by Judith McKay (Author), Tammy Schacher RN OCN MSN (Author)

Chemotherapy and Radiation For Dummies
by Alan P. Lyss (Author), Humberto Fagundes (Author), Patricia Corrigan (Author)

Stay Healthy During Chemo: The Five Essential Steps
by Mike Herbert ND (Author), Joseph Dispenza (Contributor)

Chemo: Secrets to Thriving: From someone who’s been there.
by Roxanne Brown (Author), Barbara Mastej (Contributor), John S. Link M.D. (Contributor)

Perry's The Chemotherapy Source Book
by Michael C Perry (Editor)

Questioning Chemotherapy
by Ralph W. Moss (Author)

Physicians' Cancer Chemotherapy Drug Manual 2019
by Edward Chu (Author), Vincent T. DeVita Jr. (Author)

Cooking for Chemo ...and After!: A how-to-cook cookbook that teaches you how to adjust your cooking for chemotherapy patients
by Chef Ryan Callahan (Author)

Best Science Podcasts 2018

We have hand picked the best science podcasts for 2018. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Hacking The Law
We have a vision of justice as blind, impartial, and fair — but in reality, the law often fails those who need it most. This hour, TED speakers explore radical ways to change the legal system. Guests include lawyer and social justice advocate Robin Steinberg, animal rights lawyer Steven Wise, political activist Brett Hennig, and lawyer and social entrepreneur Vivek Maru.
Now Playing: Science for the People

#495 Earth Science in Space
Some worlds are made of sand. Some are made of water. Some are even made of salt. In science fiction and fantasy, planet can be made of whatever you want. But what does that mean for how the planets themselves work? When in doubt, throw an asteroid at it. This is a live show recorded at the 2018 Dragon Con in Atlanta Georgia. Featuring Travor Valle, Mika McKinnon, David Moscato, Scott Harris, and moderated by our own Bethany Brookshire. Note: The sound isn't as good as we'd hoped but we love the guests and the conversation and we wanted to...